MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, EIKN had $56,290K increase in cash & cash equivalents over the period. -$90,063K in free cash flow.

Cash Flow Overview

Change in Cash
$56,290K
Free Cash flow
-$90,063K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from initial public off...
    • Proceeds from maturities of mark...
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Purchase of marketable securitie...
    • Accrued expenses and other curre...
    • Prepaid expenses and other curre...
    • Others

Cash Flow
2026-03-31
Net loss
-82,958
Depreciation expense
5,214
Stock-based compensation expense
2,777
Amortization of operating lease right-of-use assets
101
Amortization of premiums and accretion of discounts on marketable securities
827
Prepaid expenses and other current assets
4,377
Other assets
-2,700
Accounts payable
5,324
Accrued expenses and other current liabilities
-15,065
Operating lease liabilities
-2,488
Net cash used in operating activities
-89,801
Purchase of property and equipment
262
Purchase of marketable securities
306,955
Proceeds from maturities of marketable securities
104,000
Net cash used in investing activities
-203,217
Proceeds from issuance of common stock under stock plans
277
Proceeds from initial public offering, net of issuance costs
349,031
Net cash provided by financing activities
349,308
Net increase in cash, cash equivalents and restricted cash
56,290
Cash, cash equivalents and restricted cash at beginning of period
113,072
Cash, cash equivalents and restricted cash at end of period
169,362
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from initialpublic offering, net of...$349,031K Proceeds from issuance ofcommon stock under...$277K Net cash provided byfinancing activities$349,308K Net increase incash, cash...$56,290K Canceled cashflow$293,018K Proceeds from maturitiesof marketable...$104,000K Accounts payable$5,324K Depreciation expense$5,214K Stock-based compensationexpense$2,777K Other assets-$2,700K Net cash used ininvesting activities-$203,217K Net cash used inoperating activities-$89,801K Canceled cashflow$104,000K Canceled cashflow$16,015K Purchase of marketablesecurities$306,955K Net loss-$82,958K Accrued expenses andother current...-$15,065K Purchase of property andequipment$262K Prepaid expenses andother current assets$4,377K Operating leaseliabilities-$2,488K Amortization of premiums andaccretion of discounts on...$827K Amortization of operatinglease right-of-use...$101K

Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics, Inc. (EIKN)